Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors - Trial NCT02215928
Access comprehensive clinical trial information for NCT02215928 through Pure Global AI's free database. This phase not specified trial is sponsored by Stanford University and is currently Recruiting. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Stanford University
Timeline & Enrollment
N/A
Jul 28, 2014
Dec 01, 2024
Primary Outcome
Feasibility, measured as the proportion of patients with at least one actionable alteration
Summary
This research trial studies using genomic profiling to recommend anticancer treatment to
 patients with cancer that has spread beyond the original site of the tumor (metastatic
 cancer). Genomic profiling studies the deoxyribonucleic acid (DNA) of a tumor to detect
 genetic changes or abnormalities. This information can then be used to recommend treatments
 that may be more likely to result in a beneficial response. It is not yet known whether
 genomic profiling will detect abnormalities that can be used to make treatment
 recommendations and whether treatment based on genomic profiling is more effective than
 standard treatment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT02215928
Non-Device Trial